A Study of LY3041658 in Participants With Skin Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-08

Study Completion Date

2019-03-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3361237 in Participants With Psoriasis

NCT04975295

Psoriasis

COMPLETED PHASE1

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

NCT03418493

Psoriasis

COMPLETED PHASE1

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

NCT04152382

Psoriasis

TERMINATED PHASE1

A Study of LY3471851 in Participants With Psoriasis

NCT04119557

Psoriasis

COMPLETED PHASE1

A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis

NCT06808815

Plaque Psoriasis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Diseases Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3041658

LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).

Group Type EXPERIMENTAL

LY3041658

Intervention Type DRUG

Administered IV.

Placebo

Placebo administered IV once every two weeks over 6 weeks (four doses).

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered IV.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3041658

Administered IV.

Intervention Type DRUG

Placebo

Administered IV.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Investigator confirmed diagnosis of certain skin diseases for at least 6 months.
* Active skin lesions that are not responding to standard therapies.
* Willing to undergo pre- and post-treatment skin biopsies of lesions.